Shots:
- Brii Bio & VBI Vaccines have signed an asset purchase agreement to acquire IP rights of BRII-179 (novel recombinant protein-based HBV immunotx., expressing Pre-S1, Pre-S2 & S HBV surface antigens)
- As per the terms, Brii will acquire BRII-179’s patents, know-how & associated materials for $18M (eliminating all future milestones & royalty obligations). Prior agreements (signed in Feb 2024) will be terminated, cancelling all Brii’s payment obligations except a $2.5M promissory note, on closing
- Brii is conducting BRII-179 combination studies to improve functional cure rates for chronic HBV. In addition, recruitment in P-IIb (ENRICH) study of BRII-179 followed by elebsiran & PEG-IFNα combination has been completed
Ref: Brii Biosciences | Image: Brii Biosciences & VBI Vaccines
Related News:- Brii Biosciences Report Interim Results from P-II Study of BRII-179 (VBI-2601) + PEG-IFNα for the Treatment of Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
